Why Repligen Corp (RGEN) Stock Is Rising
As of 2026-10-15, Repligen Corp (RGEN) has a next-year EPS growth estimate of 28.40%. Featured in our EPS revision report on 2026-10-15.
Why RGEN Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Repligen Corp's next-year EPS growth estimate from 27.76% to 27.87% on 2026-10-08.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +0.53 pp to 28.40% across 2 upward revisions.
- ·Current-Year Growth: Projected at 20.66%, supporting the forward estimate revision.
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- EPS growth next year
- 28.40%
- EPS growth this year
- 20.66%
- EPS next quarter (est)
- $0.46
- Last price
- $184.77
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-15 | 28.40% | 20.66% | $0.46 | $184.77 |
| 2026-10-14 | 28.39% | 20.67% | $0.46 | $178.20 |
| 2026-10-13 | 28.58% | 20.68% | $0.46 | $175.42 |
| 2026-10-12 | 27.87% | 20.38% | $0.46 | $172.51 |
| 2026-10-11 | 27.87% | 20.38% | $0.46 | $173.88 |
| 2026-10-10 | 27.87% | 20.38% | $0.46 | $173.88 |
| 2026-10-09 | 27.87% | 20.38% | $0.46 | $173.88 |
| 2026-10-08 | 27.87% | 20.38% | $0.46 | $163.84 |
| 2026-10-07 | 27.76% | 20.38% | $0.46 | $167.22 |
| 2026-10-06 | 27.76% | 20.38% | $0.46 | $174.86 |
| 2026-10-05 | 27.81% | 20.39% | $0.46 | $189.50 |
| 2026-10-04 | 27.94% | 20.42% | $0.46 | $181.70 |
| 2026-10-03 | 27.94% | 20.42% | $0.46 | $181.70 |
| 2026-10-02 | 27.94% | 20.42% | $0.46 | $181.70 |
| 2026-10-01 | 27.94% | 20.42% | $0.46 | $177.23 |
| 2026-09-30 | 27.90% | 20.48% | $0.46 | $192.23 |
| 2026-09-29 | 27.90% | 20.48% | $0.46 | $194.57 |
| 2026-09-28 | 27.85% | 20.56% | $0.46 | $194.09 |
| 2026-09-27 | 27.85% | 20.56% | $0.46 | $189.68 |
| 2026-09-25 | 27.85% | 20.56% | $0.46 | $189.68 |
| 2026-09-24 | 27.85% | 20.56% | $0.46 | $190.65 |
| 2026-09-23 | 27.85% | 20.56% | $0.46 | $184.53 |
| 2026-09-22 | 27.85% | 20.56% | $0.46 | $186.75 |
| 2026-09-21 | 27.85% | 20.56% | $0.46 | $180.71 |
| 2026-09-20 | 27.85% | 20.56% | $0.46 | $176.89 |
| 2026-09-18 | 27.85% | 20.56% | $0.46 | $176.89 |
| 2026-09-17 | 27.85% | 20.56% | $0.46 | $178.19 |
| 2026-09-16 | 27.85% | 20.56% | $0.46 | $172.91 |
| 2026-09-15 | 27.85% | 20.56% | $0.46 | $174.73 |
| 2026-09-14 | 27.85% | 20.56% | $0.46 | $168.00 |
Reports Featuring RGEN
Recent News
- Repligen to Report Third Quarter 2026 Financial ResultsGlobeNewswire
- Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...GuruFocus.com
- Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 GuidanceInvestorsHub
- Repligen: Q2 Earnings SnapshotAssociated Press
- Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceGlobeNewswire
- Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support NetworkGlobeNewswire
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 197 days.
- Median return since detection
- -2.2%
- % of tickers in the green
- 44%
- Median return on winners
- +22.2%
- Large revisions captured
- 1879
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Repligen Corp (RGEN) stock go up recently?▾
Repligen Corp (RGEN) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 27.76% to 27.87% on 2026-10-08. Since detection, the estimate has moved up a net +0.53 pp to 28.40%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Repligen Corp's next-year EPS growth estimate?▾
As of 2026-10-15, Repligen Corp (RGEN) has a next-year EPS growth estimate of 28.40%, based on analyst consensus.
When was the latest EPS estimate revision for RGEN?▾
The most recent revision occurred on 2026-10-15, when analysts adjusted the next-year EPS growth estimate from 28.39% to 28.40%.
What sector and industry does Repligen Corp belong to?▾
Repligen Corp operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RGEN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Repligen Corp (RGEN) appears here because it was detected by our daily top-EPS-revision-performer screen.